ACAD
31.6
-0.99
-3.04%
AEMD
0.235
+0.008
+3.524%
APRI
1.86
-0.01
-0.53%
ARNA
4.2
-0.17
-3.89%
ATEC
1.4
-0.05
-3.45%
CNAT
6.83
-0.29
-4.07%
CRXM
0.19
0.00
-2.51%
CYTX
1.17
-0.01
-0.85%
DXCM
61.28
-1.06
-1.70%
GNMK
12.32
-0.66
-5.08%
HALO
14.359
+0.079
+0.553%
ILMN
182.13
-3.51
-1.89%
INNV
0.18
+0.04
+28.57%
INO
8.36
+0.2
+2.45%
ISCO
0.057
-0.001
-2.2491%
ISIS
61.74
-1.93
-3.03%
LGND
77.14
+0.03
+0.04%
LPTN
2.37
-0.1
-4.05%
MBVX
1.95
+0.08
+4.28%
MEIP
1.805
+0.015
+0.838%
MNOV
3.5
0.00
0.00%
MRTX
28.71
-0.61
-2.0801%
MSTX
0.467
-0.018
-3.6701%
NBIX
39.21
-0.5
-1.26%
NUVA
45.115
-0.875
-1.903%
ONCS
0.32
-0.015
-4.4478%
ONVO
3.78
+0.24
+6.7768%
OREX
7.625
-0.205
-2.618%
OTIC
35.4
+0.04
+0.11%
QDEL
26.14
-0.84
-3.11%
RCPT
169.595
+4.705
+2.853%
RGLS
17.11
+0.17
+1.00%
RMD
70.73
-1.05
-1.46%
SCIE
0.035
+0.005
+17.0000%
SPHS
0.589
+0.01
+1.745%
SRNE
11.33
-0.23
-1.99%
TROV
6.8
-0.01
-0.15%
VICL
0.959
+0.014
+1.4393%
VOLC
17.99
0.00
0.00%
ZGNX
1.41
+0.04
+2.92%
ACAD
31.6
-0.99
-3.04%
AEMD
0.235
+0.008
+3.524%
APRI
1.86
-0.01
-0.53%
ARNA
4.2
-0.17
-3.89%
ATEC
1.4
-0.05
-3.45%
CNAT
6.83
-0.29
-4.07%
CRXM
0.19
0.00
-2.51%
CYTX
1.17
-0.01
-0.85%
DXCM
61.28
-1.06
-1.70%
GNMK
12.32
-0.66
-5.08%
HALO
14.359
+0.079
+0.553%
ILMN
182.13
-3.51
-1.89%
INNV
0.18
+0.04
+28.57%
INO
8.36
+0.2
+2.45%
ISCO
0.057
-0.001
-2.2491%
ISIS
61.74
-1.93
-3.03%
LGND
77.14
+0.03
+0.04%
LPTN
2.37
-0.1
-4.05%
MBVX
1.95
+0.08
+4.28%
MEIP
1.805
+0.015
+0.838%
MNOV
3.5
0.00
0.00%
MRTX
28.71
-0.61
-2.0801%
MSTX
0.467
-0.018
-3.6701%
NBIX
39.21
-0.5
-1.26%
NUVA
45.115
-0.875
-1.903%
ONCS
0.32
-0.015
-4.4478%
ONVO
3.78
+0.24
+6.7768%
OREX
7.625
-0.205
-2.618%
OTIC
35.4
+0.04
+0.11%
QDEL
26.14
-0.84
-3.11%
RCPT
169.595
+4.705
+2.853%
RGLS
17.11
+0.17
+1.00%
RMD
70.73
-1.05
-1.46%
SCIE
0.035
+0.005
+17.0000%
SPHS
0.589
+0.01
+1.745%
SRNE
11.33
-0.23
-1.99%
TROV
6.8
-0.01
-0.15%
VICL
0.959
+0.014
+1.4393%
VOLC
17.99
0.00
0.00%
ZGNX
1.41
+0.04
+2.92%
Home » Archive by Category

Xconomy

After Raising $60M, Kura Oncology Renews Work on Shelved Cancer Drug

March 12, 2015 – 4:30 am

[Updated 3/12/15 9:55 am.] Even after the FDA refused to approve the anti-cancer drug tipifarnib in 2005, some experts could see a tantalizing glimmer of potential for patients with acute myeloid…

[[Click headline to continue reading.]]

At Acadia, “Mistakes Were Made,” A Drug Is Delayed & the CEO Is Out

March 11, 2015 – 4:06 pm

On Tuesday, Acadia Pharmaceuticals dropped out of two conferences and its stock price jumped, apparently because investors thought an acquisition was coming. Not quite. Instead San Diego-based Acadia…

[[Click headline to continue reading.]]

At Acadia, “Mistakes Were Made,” A Drug Is Delayed & the CEO Is Out

March 11, 2015 – 4:06 pm

On Tuesday, Acadia Pharmaceuticals dropped out of two conferences and its stock price jumped, apparently because investors thought an acquisition was coming. Not quite. Instead San Diego-based Acadia…

[[Click headline to continue reading.]]

In Move That Spells Relief, Zogenix Sells Painkiller to Pernix

March 10, 2015 – 6:50 pm

Zohydro was supposed to be a new kind of painkiller, but it gave Zogenix CEO Roger Hawley a headache that lasted more than a year. Now perhaps he can rest a little easier. After introducing Zohydro…

[[Click headline to continue reading.]]

In Move That Spells Relief, Zogenix Sells Painkiller to Pernix

March 10, 2015 – 6:50 pm

Zohydro was supposed to be a new kind of painkiller, but it gave Zogenix CEO Roger Hawley a headache that lasted more than a year. Now perhaps he can rest a little easier. After introducing Zohydro…

[[Click headline to continue reading.]]

Companion Diagnostic Specialist AltheaDx Withdraws IPO

March 10, 2015 – 8:20 am

San Diego’s AltheaDx, which offers a series of molecular diagnostic tests that enable doctors to identify the optimal drugs for treating patients, yesterday withdrew its plans for an initial public…

[[Click headline to continue reading.]]

NIH Director Hails “Stunning Case” as Example of Genomic Revolution

March 6, 2015 – 7:37 am

A pregnant mom who got a non-invasive prenatal test because she knew at age 40 that her baby was a higher risk for Down syndrome has become a case study in the potential power of precision medicine….

[[Click headline to continue reading.]]

NIH Director Hails “Stunning Case” as Example of Genomic Revolution

March 6, 2015 – 7:37 am

A pregnant mom who got a non-invasive prenatal test because she knew at age 40 that her baby was a higher risk for Down syndrome has become a case study in the potential power of precision medicine….

[[Click headline to continue reading.]]

West Coast Biotech Roundup: Pharmacyclics, Gates, Ikaria & More

March 5, 2015 – 3:01 pm

[Corrected 3/9/15, 11:46 pm. See below.] What a week for West Coast news, topped off by AbbVie’s surprise $21 billion grab of Pharmacyclics. It’s the ninth-largest biopharma acquisition…

[[Click headline to continue reading.]]

West Coast Biotech Roundup: Pharmacyclics, Gates, Ikaria & More

March 5, 2015 – 3:01 pm

[Corrected 3/9/15, 11:46 pm. See below.] What a week for West Coast news, topped off by AbbVie’s surprise $21 billion grab of Pharmacyclics. It’s the ninth-largest biopharma acquisition…

[[Click headline to continue reading.]]